Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

被引：0
|
作者：
Yasuo Suzuki
Satoshi Motoya
Hiroyuki Hanai
Takayuki Matsumoto
Toshifumi Hibi
Anne M. Robinson
Nael M. Mostafa
Jingdong Chao
Vipin Arora
Anne Camez
Roopal B. Thakkar
Mamoru Watanabe
机构：
[1] Toho University Medical Center Sakura Hospital,IBD Center
[2] Sapporo Kosei General Hospital,Department of Gastroenterology
[3] Hamamatsu South Hospital,undefined
[4] Hyogo College of Medicine,undefined
[5] Kitasato Institute Hospital,undefined
[6] AbbVie,undefined
[7] AbbVie GmbH & Co KG,undefined
[8] Tokyo Medical and Dental University,undefined
来源：
Journal of Gastroenterology | 2014年 / 49卷
关键词：
Clinical remission; Japan; Ulcerative colitis; Mucosal healing; Adalimumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：283 / 294
页数：11
相关论文
共 50 条
  • [31] Guselkumab for moderately to severely active ulcerative colitis
    不详
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 112 - 112
  • [32] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
  • [33] The efficacy and safety of adalimumab for the patients with moderate to severely active ulcerative colitis and predictors of response in Korea (EUREKA): Preliminary results
    Choi, Chang Hwan
    Park, Soo Jung
    Im, Jong Pil
    Kim, Hyo Jong
    Lee, Kang-Moon
    Kim, Ji Won
    Jung, Sung-Ae
    Lee, Jun
    Kang, Sang Bum
    Kim, You Sun
    Kim, Tae Oh
    Kim, Hyun-Soo
    Park, Dong Il
    Kim, Hyung Kil
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 66 - 67
  • [34] RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND
    Schreiber, Stefan
    Panaccione, Remo
    Parkes, Gareth C.
    Peyrin-Biroulet, Laurent
    Ferrante, Marc
    Hisamatsu, Tadakazu
    Siegmund, Britta
    Kalabic, Jasmina
    Levine, Phillip
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Cheng, Ling
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward V.
    Melmed, Gil
    Louis, Edouard
    GASTROENTEROLOGY, 2024, 166 (05) : S238 - S238
  • [35] Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis
    Wolf, D.
    D'Haens, G.
    Sandborn, W. J.
    Colombel, J. -F.
    Van Assche, G.
    Robinson, A. M.
    Lazar, A.
    Zhou, Q.
    Petersson, J.
    Thakkar, R. B.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (05) : 486 - 497
  • [36] Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
    Louis, E.
    Panaccione, R.
    Parkes, G.
    Peyrin-Biroulet, L.
    Ferrante, M.
    Hisamatsu, T.
    Siegmund, B.
    Kalabic, J.
    Levine, P.
    Neimark, E.
    Wallace, K.
    Chen, S.
    Cheng, L.
    Duan, W. R.
    Armuzzi, A.
    Biederman, L.
    Loftus, E.
    Melmed, G.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I10 - I12
  • [37] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis
    Dulai, Parambir S.
    Mosli, Mahmoud
    Khanna, Reena
    Levesque, Barrett G.
    Sandborn, William J.
    Feagan, Brian G.
    PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
  • [38] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
    Louis, Edouard
    Panaccione, Remo
    Parkes, Gareth
    Peyrin-Biroulet, Laurent
    Ferrante, Marc
    Takeuchi, Ken
    Siegmund, Britta
    Levine, Phillip
    Kalabic, Jasmina
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward V.
    Melmed, Gil
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S624 - S625
  • [39] Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen
    Strauss, Rick
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    Tarabar, Dino
    GASTROENTEROLOGY, 2016, 150 (04) : S776 - S777
  • [40] Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
    Louis, Edouard
    Panaccione, Remo
    Parkes, Gareth
    Pevrin-Biroulet, Laurent
    Ferrante, Marc
    Takeuchi, Ken
    Siegmund, Britta
    Levine, Phillip
    Kalabic, Jasmina
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward
    Melmed, Gil
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S3 - S3
12345